Atlas Trials

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

Clinical trial NCT02008916 · COMPLETED

Trial details

NCT number
NCT02008916
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Spondylitis, Ankylosing
Start date
2014-01-14
Primary completion
2015-02-23
Enrollment
226

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.